Research programme: GPR120 agonists - Dompe
Latest Information Update: 19 Jul 2016
At a glance
- Originator Dompe SpA
- Mechanism of Action GPR120 protein stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Diabetes mellitus
Most Recent Events
- 19 Jul 2016 Early research in Diabetes mellitus in Italy (unspecified route)